ArticleProceedings of the National Academy of Sciences of the United States of America2014
Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
105 citing papers in PubMed, 1 synthesis or guideline pooled it, 162 citations in OpenAlex.
- The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers.Molecules (Basel, Switzerland) · 2021Pooled it
- Metabolic [¹⁸F]F-AraG PET imaging of T Cell activation: a functional complement to cell-specific immune tracers.EJNMMI research · 2026Review
- Emerging ImmunoPET probes for precision cancer immunotherapy: molecular targets and translational applications.Frontiers in oncology · 2026Review
- [European journal of nuclear medicine and molecular imaging · 2025Article
- Development of a novelJournal for immunotherapy of cancer · 2025Article
- Reengineered Anti-CD4 Cys-diabody Variants forMolecular imaging and biology · 2025Article
- Head-to-head comparison of nuclear imaging approaches to quantify tumor CD8Immunotherapy advances · 2025Article
- Single Chelator-Minibody Theranostic Agents forJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Integrating Artificial Intelligence and PET Imaging for Drug Discovery: A Paradigm Shift in Immunotherapy.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Shortwave-Infrared-Emitting Nanoprobes for CD8 Targeting and In Vivo Imaging of Cytotoxic T Cells in Breast Cancer.Advanced nanobiomed research · 2024Article
- The role of CD8 PET imaging in guiding cancer immunotherapy.Frontiers in immunology · 2024Review
- [Theranostics · 2024Article
- Illuminating immunotherapy response via precision T cell-targeted PET imaging.Frontiers in medicine · 2024Review
- Simultaneous quantitative imaging of two PET radiotracers via the detection of positron-electron annihilation and prompt gamma emissions.Nature biomedical engineering · 2023Article
- Advances in PET imaging of cancer.Nature reviews. Cancer · 2023Review
- Immuno-PET Monitoring of CD8Molecular imaging and biology · 2023Article
- Implication ofJournal for immunotherapy of cancer · 2023Article
- PET/MR imaging of inflammation in atherosclerosis.Nature biomedical engineering · 2023Review
- Current and potential roles of immuno-PET/-SPECT in CAR T-cell therapy.Frontiers in medicine · 2023Review
- Elucidating the neuroimmunology of traumatic brain injury: methodological approaches to unravel intercellular communication and function.Frontiers in cellular neuroscience · 2023Review
45 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
The noninvasive detection and quantification of CD8(+) T cells in vivo are important for both the detection and staging of CD8(+) lymphomas and for the monitoring of successful cancer immunotherapies, such as adoptive cell transfer and antibody-based immunotherapeutics. Here, antibody fragments are constructed to target murine CD8 to obtain rapid, high-contrast immuno-positron emission tomography (immuno-PET) images for the detection of CD8 expression in vivo. The variable regions of two anti-murine CD8-depleting antibodies (clones 2.43 and YTS169.4.2.1) were sequenced and reformatted into minibody (Mb) fragments (scFv-CH3). After production and purification, the Mbs retained their antigen specificity and bound primary CD8(+) T cells from the thymus, spleen, lymph nodes, and peripheral blood. Importantly, engineering of the parental antibodies into Mbs abolished the ability to deplete CD8(+) T cells in vivo. The Mbs were subsequently conjugated to S-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid for (64)Cu radiolabeling. The radiotracers were injected i.v. into antigen-positive, antigen-negative, immunodeficient, antigen-blocked, and antigen-depleted mice to evaluate specificity of uptake in lymphoid tissues by immuno-PET imaging and ex vivo biodistribution. Both (64)Cu-radiolabeled Mbs produced high-contrast immuno-PET images 4 h postinjection and showed specific uptake in the spleen and lymph nodes of antigen-positive mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.